Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Targeting BRAF in thyroid cancer Espinosa AV; Porchia L; Ringel MDBr J Cancer 2007[Jan]; 96 (1): 16-20Activating mutations in the gene encoding BRAF are the most commonly identified oncogenic abnormalities in papillary thyroid cancer. In vitro and in vivo models have demonstrated that overexpression of activated BRAF induces malignant transformation and aggressive tumour behaviour. BRAF and other RAF kinases are frequently activated by other thyroid oncogenes and are important mediators of their biological effects including dedifferentiation and proliferation. Because current therapeutic options for patients with thyroid cancers that are aggressive and/or do not respond to standard therapies are limited, BRAF and its downstream effectors represent attractive therapeutic targets. In this review, data supporting a role for BRAF activation in thyroid cancer development and establishing the potential therapeutic efficacy of BRAF-targeted agents in patients with thyroid cancer will be reviewed.|Enzyme Activation/drug effects/genetics[MESH]|Enzyme Inhibitors/pharmacology[MESH]|Gene Expression Regulation, Neoplastic/genetics[MESH]|Humans[MESH]|Mutation[MESH]|Proto-Oncogene Proteins B-raf/antagonists & inhibitors/genetics/*metabolism[MESH]|Structure-Activity Relationship[MESH]|Thyroid Neoplasms/drug therapy/genetics/*metabolism[MESH]|raf Kinases/genetics/metabolism[MESH] |